

VOLUME II

Index of Tables and Figures

PAD Consequences	4
Consequences of Critical Limb Ischemia	5
Consequences of First Stroke	5
Percentage of Patients with Intermittent Claudication	6
Cause of Death in PAD	8
Five-Year All-Cause Mortality for Selected Diseases	9
Ten-Year Mortality for PAD by Disease Severity Compared to Survivors of First Heart Attack	9
Percentage of PAD Patients with Coronary Artery Disease (CAD) or Cerebrovascular Disease (CVD)	10
Ankle Brachial Index (ABI)	10
Five-Year Mortality and Incidence of Non-Fatal MI or Stroke	11
ABI and PAD Severity and Symptoms	12
Treatment of PAD	13
Revascularization	14
Type I Disease	17
Type II Disease	18
Type III Disease	18
PAD - Disease and Lesion Classification Systems	19
Definitions of Interventional Success	21
Advantages and Disadvantages of Bypass Surgery	24
Indications for Bypass Surgery	24
Bypass Surgery Recommended for These Types of Lesions	25
Bypass Surgery - Outcome Measurements	26
Bypass Surgery - Comparison of Five-Year Patency by Graft Type Autologous (AVG) and Synthetic (SVG)	27
Complications of Peripheral Bypass Surgery	27
Types of Bypass Grafts	28
Graft Manufacturers	29
Endovascular Treatments For Peripheral Arterial Disease	32
Peripheral Angioplasty	33
Variables in Successful PTA	34
Complications of PTA	34
Antiplatelets	35

U.S. Peripheral Endovascular Market	39
Stent Complications	40
Atherectomy Devices	41
Aortoiliac Disease	43
Aortoiliac Disease - Choice of PTA or Surgery	44
PTA Preferred Treatment For These Iliac Lesions (TASC Type A)	45
PTA May Be Used For These Iliac Lesions (TASC Type B/C)	45
Surgery Recommended Treatment For These Iliac Lesions (TASC Type D)	45
Aortoiliac Revascularization Comparison of PTA and Bypass Surgery	46
Comparison of PTA and Stents - Aortoiliac Procedures	47
Peripheral Balloon-Expandable Stents	51
Peripheral Self-Expanding Stents	52
CRISP US Study - Comparison of Selected Results - SMART and Wallstent	54
Peripheral Covered Stents.....	55
Femoropopliteal Disease with SFA Occlusion	59
Characteristics Femoropopliteal Disease	60
Optimal Conditions for Successful Femoral PTA	60
Femoropopliteal and Aortoiliac PTA - Comparison of Success and Complications By Lesion Type	61
Comparison of PTA and Bypass Femoropopliteal	63
Mode of Failure, Treatment Options and Cost For Femoropopliteal Bypass Surgery and PTA	64
Indications for Femoropopliteal Stents	67
Restenosis in Femoropopliteal Stenting	67
Stents in The SFA Patency and Restenosis Selected Results of Nine Studies 1989 - 1997	69
Femoropopliteal Comparison of Bypass Surgery and PTA with Stents Results of Selected Studies	70
Infrainguinal Self-Expanding Stents	73
Comparison of Restenosis Rates Between Stainless Steel and Nitinol Stents in the Femoropopliteal Arteries	75
Femoropopliteal Self-Expanding Nitinol Stents Early Results of Selected Studies In Stenoses and Occlusions	76
Femoropopliteal Stent-Grafts Results of Three Studies Employing the Hemobahn Endoprosthesis	79
Peripheral Drug-Eluting Stents Published Clinical Trials	81
New Devices for Crossing CTOs Peripheral Results	85
Tibioperoneal Disease Accompanied by SFA Stenosis	90
Limited Indications for Below-the-Knee PTA	90
Tibial PTA Success and Complication Rates	90

Infrapopliteal PTA and Surgery For Critical Limb Ischemia Selected Outcomes	92
Critical Limb Ischemia - Limb Salvage Rates - Comparison of Selected Endovascular Technologies	95
Critical Limb Ischemia Consequences of Treatment Options in Poor Surgical Candidates	98
Critical Limb Ischemia Cost Comparison of Amputation and Revascularization	100
Estimated Number of People with PAD 2000 - 2020	101
Primary and Revision Peripheral Bypass Procedures 1983-2000 (Non-Federal and VA Hospitals)	103
Primary Peripheral Bypass Procedures 1983-2000 (Non-Federal and VA Hospitals)	104
Peripheral Interventional Procedures 1983-2000 Aortoiliac Bypass (AI-BP), Infrainguinal Bypass (II-BP) and Angioplasty (PTA)	105
Estimated Percentage of Peripheral Bypass Procedures Performed By Indication 1985 and 2000	107
Estimated Total Amputations Related to Peripheral Disease 1983-2000	108
2000 U.S. PAD Market Potential For Interventional Therapy (IT) By Disease Severity	110
2000 U.S. PAD Market Potential For Bypass (BP) and Endovascular Therapy (ET) By Disease Severity	111
2000 U.S. PAD Market Potential For Bypass Surgery (BP) By Disease Severity (Limbs)	112
2000 U.S. PAD Market Potential For Endovascular Therapy (ET) By Disease Severity (Limbs)	113
2000-2020 U.S. PAD Market Potential For Bypass Surgery (BP) and Endovascular Therapy (ET) As the Population Ages (Limbs)	114
2003 U.S. PAD Market for Bypass (BP) - Current Market Compared to Potential Market (Procedures)	115
2000-2010 Projected Growth of Current Bypass Market and Potential Market If Percentage of Patients Diagnosed Increases to 30%	116
2000-2010 Projected Growth of Current Bypass Market and Potential Market If Percentage of Patients Diagnosed Increases to 35%	117
PAD 2003 U.S. PAD Market for Endovascular Therapy (ET) - Current Market Compared to Potential Market (Procedures)	118
2000-2010 Projected Growth of Current Endovascular Market and Potential Market If Percentage of Patients Diagnosed Increases to 30%	119
2000-2010 Projected Growth of Current Endovascular Market and Potential Market If Percentage of Patients Diagnosed Increases to 35%	120
2003 U.S. PAD Market Potential For Primary and Redo Bypass Surgery (BP) By Disease Severity (Limbs)	121
2000-2020 U.S. PAD Market Potential For Primary and Redo Bypass Surgery By Disease Severity (Limbs)	122
2003 U.S. PAD Market Potential For Primary and Redo Endovascular Therapy (ET) By Disease Severity (Limbs).	123

